DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Tahara M, Brose MS, Wirth LJ. et al.
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in
patients with radioiodine-refractory differentiated thyroid cancer.
Eur J Cancer 2019;
106: 61-68
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.